SCY-635

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C66H120N12O13S
Molecular Weight	1321.797
Optical Activity	UNSPECIFIED
Defined Stereocenters	13 / 13
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)(C)O)N(C)C(=O)[C@@H](SCCN(C)C)N(C)C1=O)C(C)C

InChI

InChIKey=AQHMBDAHQGYLIU-XNFHFXFQSA-N

InChI=1S/C66H120N12O13S/c1-27-29-30-42(13)53(79)52-57(83)69-45(28-2)59(85)78(26)65(92-32-31-71(18)19)64(90)75(23)49(36-66(16,17)91)56(82)70-50(40(9)10)62(88)72(20)46(33-37(3)4)55(81)67-43(14)54(80)68-44(15)58(84)73(21)47(34-38(5)6)60(86)74(22)48(35-39(7)8)61(87)76(24)51(41(11)12)63(89)77(52)25/h27,29,37-53,65,79,91H,28,30-36H2,1-26H3,(H,67,81)(H,68,80)(H,69,83)(H,70,82)/b29-27+/t42-,43+,44-,45+,46+,47+,48+,49+,50+,51+,52+,53-,65-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C66H120N12O13S
Molecular Weight	1321.797
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	13 / 13
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT01265511 | https://www.ncbi.nlm.nih.gov/pubmed/22425702 | https://adisinsight.springer.com/drugs/800025202

SCY-635 is a nonimmunosuppressive cyclosporine-based analog that exhibits potent suppression of hepatitis C virus (HCV) replication. SCY-635 has reached the phase II clinical trial for the treatment of patients with hepatitis C Infection. In addition, in the preclinical model, the SCY-635 was studied for the treatment of hepatitis-B in USA.

Originator

Approval Year

PubMed

Title	Date	PubMed
The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes.	2012-07	22585215
The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection.	2012-07	22425702
SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.	2010-02	19933795

Sample Use Guides

In Vivo Use Guide

SCY-635 tablets, 300 mg bid for 28 days

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:01:09 GMT 2025` Edited by `admin` on `Mon Mar 31 23:01:09 GMT 2025`
Record UNII	WSU5343074
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CYCLOSPORIN A, 8-((2R)-2-((2-(DIMETHYLAMINO)ETHYL)THIO)-N-METHYLGLYCINE)-9-(4-HYDROXY-N-METHYL-L-LEUCINE)-

Preferred Name

English

SCY-635

Common Name

English

Code System Code Type Description

CAS

210759-10-7